VK Singh: Advocating Collaborative Leadership & Innovation As The Key To Success
VK Singh
COO
VK desists micromanaging and draws his zeal from pursuing ambitious long term objectives, charting a course that steers his company towards the pinnacle of success. VK's journey commenced with FMCG with a brief stint overseas as a commodities trader till destiny eventually brought him to the sunrise industry of pharmaceuticals, which he has served ever since.
In an exclusive interview with CEO Insights Magazine, VK Singh walks us through his journey along with the unique positioning of the company.
You possess over twenty-three years of experience. How has been your path to success and what is your success mantra?
Success springs from cohesive teamwork, not solitary endeavors. Collaboration's power is a lesson from our hunter-gatherer past. A robust team, formed from the outset, charts the path to triumph. I seek multipliers when hiring, not just individuals with competence or knowledge. Together, we amplify capabilities, propelling forward. Small teams, united by a common purpose, unlock value faster. Each member harmonizes efforts, contri
buting uniquely. Transparency in recognizing merit and rewarding performance fosters a prejudice-free and flourishing meritocracy. For us work is our core, and efforts are acknowledged and celebrated, wherein, a merit based culture fuels success, valuing all contributions. My mantra for success has been building cohesive and fleet-footed teams embracing meritocracy and cherishing collective accomplishments. Together, our collaborative spirit drives us towards shared goals and achievements.
How would you define Blue Jet Healthcare as an organization and its current positioning in the market?
Blue Jet Healthcare is a pure-play, boutique CDMO in India, with specialized chemistry platforms and RnD capabilities. We exclusively serve innovator companies and MNCs in niche and non-genericized segments like performance chemicals used for imaging such as X-rays and CT Scans by the Medtech Industry. We also develop and supply intermediates for several pharmaceutical drugs which are often still under patent or being niche are not yet genericized. We offer the full gamut of services, right from bench to bulk manufacturing at industrial scale in our world-class cGMP facilities. Our highly experienced developmental quality assurance (DQA) and regulatory affairs teams ensure that the development is as per Quality by Design for which the Design of Experiments is based on scientific rationale for process robustness and reproducibility. With a balanced approach to development and manufacturing, we cater to niche segments efficiently, providing end-to-end solutions to our valued clients. As most CDMOs bring expertise in either development or manufacturing, we at Blue Jet Healthcare have carved a niche as a reliable and trustworthy partner for both.
Tell us about your leadership approach. What are the guidelines or methodologies you follow as a leader?
My approach is more consultative and participative as that inculcates higher ownership and engagement and is far less directional. Most decision-making is therefore collective. I listen to the team's
We aim to stay at the forefront of advance- ments, driving growth & delivering value to our clients
How would you define Blue Jet Healthcare as an organization and its current positioning in the market?
Blue Jet Healthcare is a pure-play, boutique CDMO in India, with specialized chemistry platforms and RnD capabilities. We exclusively serve innovator companies and MNCs in niche and non-genericized segments like performance chemicals used for imaging such as X-rays and CT Scans by the Medtech Industry. We also develop and supply intermediates for several pharmaceutical drugs which are often still under patent or being niche are not yet genericized. We offer the full gamut of services, right from bench to bulk manufacturing at industrial scale in our world-class cGMP facilities. Our highly experienced developmental quality assurance (DQA) and regulatory affairs teams ensure that the development is as per Quality by Design for which the Design of Experiments is based on scientific rationale for process robustness and reproducibility. With a balanced approach to development and manufacturing, we cater to niche segments efficiently, providing end-to-end solutions to our valued clients. As most CDMOs bring expertise in either development or manufacturing, we at Blue Jet Healthcare have carved a niche as a reliable and trustworthy partner for both.
Tell us about your leadership approach. What are the guidelines or methodologies you follow as a leader?
My approach is more consultative and participative as that inculcates higher ownership and engagement and is far less directional. Most decision-making is therefore collective. I listen to the team's
suggestions and ideas, and we agree on the best course of action. Execution is crucial for success, out weighing planning and conceptualization. While mostly, I act as an influencer or mentor, on some occasions, I take a more directional approach when people’s biases or prejudices affect decisions or preconceived notions start to color opinions, but such instances are rare. Overall, I value collaboration and inclusivity to ensure the organization's success.
What is the future destination you are heading towards?
As a CDMO, capacity and RnD capability, are two key pivots. Over the past four years, we have made significant investments in our capacity expansion projects, resulting in a quadrupling of our overall capacity. This strategic approach has positioned us favorably in the market, allowing us to meet growing demands and remain competitive. Moreover, we have devoted substantial efforts to enhance our Research and Development (R&D) capabilities over the last year. Through expanding our platforms, augmenting hardware resources, and recruiting top-notch talent, we have significantly enhanced our R&D capacity and capability. This heightened focus on R&D has been pivotal to our success as a Contract Development and Manufacturing Organization (CDMO). Looking ahead, we are committed to sustaining this momentum. Recognizing its paramount importance in our industry, we shall continue to prioritize investments in research and innovation. By doing so, we aim to stay at the forefront of advancements, driving growth, and delivering value to our clients.
In the light of your strong experience within the industry, what advice would you give to the budding industry leaders?
The pharma industry operates in a highly regulated environment. Pharmaceutical and the niche Medtech oriented performance chemicals that we manufacture are no different. Due to these regulatory and compliance implications, we tend to be late adopters of new technologies. We must change that. We must be early adopters and incubators to stay ahead of the curve. Embracing innovation will lead us to success while meeting regulatory standards.
VK Singh, Chief Operating Officer, Blue Jet Healthcare
VK Singh, Chief Operating Officer, Blue Jet Healthcare, is an esteemed Chemical Engineer from IIT Kanpur and boasts of a remarkable 23 - year track record in the pharmaceutical domain.
What is the future destination you are heading towards?
As a CDMO, capacity and RnD capability, are two key pivots. Over the past four years, we have made significant investments in our capacity expansion projects, resulting in a quadrupling of our overall capacity. This strategic approach has positioned us favorably in the market, allowing us to meet growing demands and remain competitive. Moreover, we have devoted substantial efforts to enhance our Research and Development (R&D) capabilities over the last year. Through expanding our platforms, augmenting hardware resources, and recruiting top-notch talent, we have significantly enhanced our R&D capacity and capability. This heightened focus on R&D has been pivotal to our success as a Contract Development and Manufacturing Organization (CDMO). Looking ahead, we are committed to sustaining this momentum. Recognizing its paramount importance in our industry, we shall continue to prioritize investments in research and innovation. By doing so, we aim to stay at the forefront of advancements, driving growth, and delivering value to our clients.
In the light of your strong experience within the industry, what advice would you give to the budding industry leaders?
The pharma industry operates in a highly regulated environment. Pharmaceutical and the niche Medtech oriented performance chemicals that we manufacture are no different. Due to these regulatory and compliance implications, we tend to be late adopters of new technologies. We must change that. We must be early adopters and incubators to stay ahead of the curve. Embracing innovation will lead us to success while meeting regulatory standards.
VK Singh, Chief Operating Officer, Blue Jet Healthcare
VK Singh, Chief Operating Officer, Blue Jet Healthcare, is an esteemed Chemical Engineer from IIT Kanpur and boasts of a remarkable 23 - year track record in the pharmaceutical domain.